Should antidiabetic treatment of type 2 diabetes in patients with heart failure differ from that in patients without? (Q27022813)

Petra-Maria Schumm-Draeger

7

object named as

Petra-Maria Schumm-Draeger

0 references

Diethelm Tschöpe

9

object named as

Diethelm Tschöpe

0 references

Nikolaus Marx

5

object named as

Nikolaus Marx

1 reference

Anselm K. Gitt

1

1 reference

Martin Halle

2

1 reference

Monika Kellerer

4

1 reference

Juris J. Meier

6

1 reference

Petra-Maria Schumm-Draeger

7

1 reference

Peter Bramlage

8

1 reference

Diethelm Tschöpe

9

1 reference

language of work or name

1 reference

December 2012

1 reference

European Journal of Heart Failure

published in

1 reference

volume

14

1 reference

page(s)

1389-400

1 reference

issue

12

1 reference

Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study.

cites work

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS136

Role of diabetes in congestive heart failure: the Framingham study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS136

New type of cardiomyopathy associated with diabetic glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS136

Risk of heart failure in patients with recent-onset type 2 diabetes: population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS136

Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS136

Diabetic cardiomyopathy revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS136

Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS136

21 January 2018

Diabetic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS136

Effect of an exercise training program on endothelial dysfunction in diabetic and non-diabetic patients with severe chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS136

Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS136

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS136

Metformin treatment in diabetes and heart failure: when academic equipoise meets clinical reality

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS136

Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS136

Metformin use and mortality in ambulatory patients with diabetes and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS136

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS136

Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS136

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS136

Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS136

Comparison of pioglitazone vs glyburide in early heart failure: insights from a randomized controlled study of patients with type 2 diabetes and mild cardiac disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS136

Improved clinical outcomes associated with metformin in patients with diabetes and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS136

Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS136

The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS136

A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS136

Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS136

Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS136

A randomized trial of therapies for type 2 diabetes and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS136

Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS136

Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS136

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS136

Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS136

Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS136

Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS136

Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS136

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS136

Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS136

Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS136

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS136

Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS136

Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS136

Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS136

Insulin-treated type 2 diabetes is associated with a decreased survival in heart failure patients after cardiac resynchronization therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS136

Thiazolidinediones and Heart Failure: A teleo-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS136